Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Dual PD-1 checkpoint inhibitor/undisclosed target |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), GPC3 inhibitors(Glypican-3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Preclinical | CN | 30 Jan 2022 | |
Hepatocellular Carcinoma | Preclinical | US | 30 Jan 2022 |